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Problem identification: The desire for motherhood is one of the top priorities for most female young 
cancer survivors. The risk of infertility after cancer therapy is an important concern with several phys-
ical and emotional consequences. This comprehensive literature review aims to summarize and con-
textualize recent research that has been carried out on female fertility after cancer, suggesting future 
research and clinical directions. 
Literature search: Searches included the key words “cancer”, “female”, “adults”, and “fertility”. Studies 
were selected if focused on infertility issues in female cancer survivors. 
Data synthesis: Eight themes were identified: the effects of anticancer treatments on fertility, fertility 
preservation methods, international recommendations regarding infertility risk, health professionals’ 
attitudes towards fertility preservation, patients’ concerns regarding the risk of infertility, patients’ in-
formation needs, and the impact of the risk of infertility in patients’ quality of life.
Conclusions: Psycho-oncologists should be integrated in the oncofertility teams to assess patients’ 
needs before cancer treatment initiation. 
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in developing countries, over the last decades, cancer is increas-
ingly common in women of childbearing age [1, 2]. Breast cancer, 
cervical cancer, thyroid cancer, non-Hodgkin’s lymphoma, and 
leukemia are the most frequent cancers among women younger 
than 40 [3].
Due to advances in early diagnosis, improved treatment proto-
cols, and individualized therapies, cancer survival rates are cur-
rently exceeding 80% for some of these cancer types [4]. These 
higher survival rates increase the importance placed on survivor-
ship issues, such as infertility risk [5]. 
The desire for motherhood is one of the top priorities for most 
young female cancer survivors [6]. according to recent studies, 
75% of women between 18 and 45 years old with a diagnosis of 
cancer wish to have children [7]. With the recent voluntary de-
ferral of procreation, especially seen in Western societies, many 
women, at the time of diagnosis, have yet to initiate family or have 
not yet completed their family wishes. although surrogacy and 
adoption can be an option, many women voice a preference for 
biological parenting [8]. 
Since thousands of cancer patients and survivors are in their 
reproductive age and the risk of infertility after cancer is a  real-
ity that these women must face, discussing fertility after cancer 
treatment is a subject of great clinical importance. Women should 
have the opportunity to plan the desired motherhood, given that 
several methods are already well-established and available [2].
in this context, oncofertility emerges as a  clinical specialty that 
aims to understand cancer patients and survivors’ needs regard-
ing their reproductive potential before, during, and after antineo-
plastic treatments [9]. given the international recommendations 
[10, 11], physicians should advocate for the timely provision of fer-
tility information, for the patients’ referral to fertility preservation 
methods [12], and for the importance of establishing oncofertility 
consults as a part of current medical practice in oncology centers 
[10, 11].
in the present paper, a  comprehensive literature review is pre-
sented that intends to summarize and contextualize recent re-
search that has been carried out on female fertility after cancer 
therapy, suggesting future research and clinical directions that 
aim to optimize patient psychosocial care during survival.
METHODOLOGY
Two authors (Sousa and Pereira) performed the search and care-
fully reviewed the published literature listed in PubMed and Psy-
cinFo from January 2010 to December 2020. Hence, all searches 
included the key words “cancer”, “female”, “adults”, and “fertility”. 
limits were applied for searches based on tittles and abstracts. 
The three authors (Sousa, castro and Pereira) independently se-
lected the most relevant articles considering this review’s goals. 
Studies were selected if focused on the exploration of infertility 
issues in female cancer survivors. other reviews on the topic were 
also considered and retrieved from the same databases. articles 
were excluded if not written in English or Portuguese. all arti-
cles and its pertinence to the present review were discussed and 
a  consensus was reached based on the most frequent themes 
that were found. 
RESULTS
To make the search results easier to describe, this comprehensive 
review presents different subheadings: effects of anticancer treat-
ments on fertility, fertility preservation methods, international 
recommendations regarding infertility risk, health professionals’ 
attitudes towards fertility preservation, patients’ concerns and at-
titudes regarding the risk of infertility, patients’ information needs 
regarding fertility preservation, and the impact of the risk of infer-
tility on patient’s quality of life.
EFFECTS OF ANTICANCER TREATMENTS ON FERTILITY
The negative effect of cancer therapy on female fertility is well-
known. Some chemotherapeutic agents, abdominal or pelvic 
radiation, bone marrow transplantation, and surgery for gyne-
cological malignancies, have a high risk of gonadal damage [13]. 
Especially chemotherapy and endocrine treatments have experi-
enced a significant increase in the last decade [14, 15]. These an-
tineoplastic treatments may partially or definitively affect ovarian 
function and lead to early menopause with all of its inherent risks, 
including infertility, that may be temporary or permanent [16]. 
adjuvant chemotherapy, particularly with alkylating agents (e.g., 
cyclophosphamide, ifosfamide, chlorambucil, melphalan, busul-
fan, and procarbazine), poses the greatest risk of significant or 
permanent damages to female fertility [17]. These agents are 
responsible for high gonadotoxicity and amenorrhea in 18% to 
61% of women under 40 [16]. in hormone-dependent breast can-
cer tumors, pre-menopausal women are also prescribed hormo-
nal replacement therapy, such as tamoxifen [14]. in these cases, 
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women are advised to postpone their pregnancy for a minimum 
of 2 to 5 years, since the risk of recurrence is higher in this period 
[18]. This hormonal treatment is proposed for a minimum of five 
years; nevertheless, extending tamoxifen up to ten years rather 
than stopping at five, has been proven to further reduce recur-
rence and mortality [19]. This extension has been incorporated 
into the international guidelines for cancer treatment preventing 
women from considering pregnancy, as fertility is also likely to be 
reduced due to age-related biological decline [20]. 
nonetheless, these patients should not be discouraged to be-
come pregnant, since recent studies suggested that pregnancy 
did not adversely affect survival in female cancer survivors [21]. 
Research also revealed that local or systemic anticancer treat-
ments posed no further risks for the offspring of cancer survivors. 
However, there is a higher risk for miscarriage in these situations 
[22]; therefore, there are some necessary prerequisites that should 
be considered when supporting a  pregnancy after cancer. The 
interval between treatment and conception is one of the most 
important considerations, since women who conceived less than 
one year after chemotherapy, had higher risks of preterm birth 
than women who conceived 2 years or more after treatment [23]. 
FERTILITY PRESERVATION METHODS
increasing survival rates in female cancer survivors of reproduc-
tive age have led to the development and increased use of several 
fertility preservation techniques [2]. However, fertility preserva-
tion procedures are usually expensive and time-consuming [24]. 
Different techniques can be presented before treatment initia-
tion, based on the patient’s age and health status, as well as the 
risk of ovarian involvement [24].
Embryo cryopreservation is the most well-established option for 
female fertility preservation, as recognized by aSco (american 
Society of clinical oncology) and aSRM (american Society for Re-
productive Medicine) [10, 11]. This procedure involves an ovary 
stimulation period with daily injections of gonadotrophins and 
ultrasonographic monitoring of follicle growth, which requires 
exposure to high levels of estrogen and a delay in systemic treat-
ment commencement for at least 2 to 3 weeks. This method also 
implies that there is a source of male gametes, sometimes causing 
the exclusion of women who do not have a steady partner [24]. 
in these situations, other viable options can be presented such 
as the cryopreservation of oocytes, which also requires an ovar-
ian stimulation procedure, a subsequent follicular puncture, and 
cryopreservation obtained by vitrification. This last technique has 
significantly improved the survival of oocytes, fertilization rates, 
and the ratio of high-quality embryos due to slow freezing, allow-
ing better conservation results [11].
in addition to these two methods, there are other experimental 
options, such as ovarian tissue cryopreservation, especially use-
ful when hormonal stimulation is undesirable and/or there is ur-
gency in anticancer treatment initiation. This technique involves 
a  laparoscopic surgery for harvesting a  fragment of the ovary. 
Hereafter, the ovarian tissue is properly prepared and cortex frag-
ments are isolated for cryopreservation. Whenever necessary, 
the fragments are thawed and grafted on the remaining ovary – 
orthotopic transplantation – or in another location – heterotopic 
transplantation. after transplantation, the ovarian tissue can re-
store its endocrine function and fertility [24]. concerning gonado-
tropin-releasing hormone agonist (gnRHa), the evidence is still in-
conclusive regarding its isolated success for fertility preservation 
during chemotherapy [11].
aSco has recently updated its guidelines for fertility preserva-
tion in cancer patients. When is clinically safe and the patient has 
time before treatment commencement, aSco recommends that 
oocyte cryopreservation should be offered [11]. Besides, ovarian 
cryopreservation is another procedure with great potential in the 
near future [24].
Therefore, with the recent advances in biomedicine and tech-
nology, the probability of childbearing after aggressive antineo-
plastic treatments is constantly increasing. nevertheless, fertility 
outcomes in oncology patients have not been adequately stud-
ied given the small percentage of patients that attempted to get 
pregnant after cancer. Many studies have reported good results 
of these procedures, but only a few of them reported pregnancy 
outcomes in patients returning to use their embryos or oocytes 
after cancer [5, 13]. 
INTERNATIONAL RECOMMENDATIONS REGARDING 
INFERTILITY RISK
aSco recommendations regarding fertility preservation encour-
age oncologists to address the risk of infertility with their patients 
treated during childbearing years, to discuss fertility preservation 
options, and to refer them to reproductive specialists [11, 25]. 
First, patients should be informed about the feasibility of pur-
suing fertility preservation options and its dependency on each 
patient’s recurrence risk, prognosis, and risk of infertility or early 
menopause from oncology therapy. next, fertility preservation 
options should be discussed with their respective success rates, 
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including those considered experimental. clinicians should also 
explain that fertility procedures may be expensive and time-con-
suming and, therefore, imply antineoplastic treatment delay [11]. 
Thus, a prompt referral to a fertility specialist would optimize the 
time between diagnosis and cancer treatment commencement 
[25]. Meeting with a social worker may also be beneficial to sup-
port the decision-making process, to consider the financial re-
sources and the associated costs of this procedure [26].
although these guidelines represent a step forward, additional 
efforts are needed to encourage clinicians to include infertility 
risk as part of the standard discussion for all cancer patients with-
in reproductive years. This topic is not consistently addressed 
in clinical practice, despite the aforementioned aSco recom-
mendations [11, 26], and the provision of fertility preservation 
techniques is still lacking. improvements need to be made in the 
number of referrals from oncology to reproductive medicine spe-
cialists [25].
HEALTH PROFESSIONALS’ ATTITUDES TOWARDS 
FERTILITY PRESERVATION 
Many factors impact patients’ access to fertility preservation in-
formation. a few studies explored health professionals’ concerns 
regarding fertility preservation and, although evidence suggest-
ed greater awareness, knowledge, and willingness to discuss this 
topic with patients, many patients still report receiving little in-
formation [27, 28]. in this sense, a recent study reported that only 
49.5% of physicians routinely informed their patients of childbear-
ing age about the risk of infertility after cancer treatment [29]. 
Several barriers were identified regarding communication con-
cerning fertillity preservation, namely the clinician insufficient 
knowledge regarding the available fertility preservation options, 
the lack of communication and access to reproductive specialists, 
and patients’ characteristics (e.g., prognosis, age, parental status, 
marital status, financial capacity, sexual orientation, sexual ma-
turity, and whether or not the patients initiate the conversation) 
[28]. also, the clinicians’ perception of fertility as a minor issue, the 
fear of disease aggravation due to anticancer treatment delay, the 
availability of educational materials, as well as legal and ethical 
issues such as the subsequent use of male gametes, were some 
of the additional barriers reported [28]. However, the amount of 
time spent with patients was described as one of the strongest 
barriers to discuss fertility issues with female cancer survivors [30].
These informational and communication barriers may prejudice 
and bias the patient’s decision-making processes [31]. Thus, it is 
of utmost importance to overcome the intrinsic barriers justifying 
why oncologists do not discuss fertility risk issues with their pa-
tients, namely the lack of communication skills [30], and the on-
cologists’ perceptions of patients’ characteristics as dictating their 
willingness to undergo fertility preservation. 
Future work should ensure that health care professionals receive 
adequate training on how to discuss fertility risk and preservation 
options with young patients and their partners. comprehensive 
counseling should also include related issues such as contracep-
tion use and the health implications of early menopause [32]. 
nevertheless, it is also important to recognize that the discussion 
of fertility prognosis and risk of recurrence at the time of diagno-
sis, may become an additional burden for clinicians. communica-
tion skills should also be trained by consulting with other health 
providers, such as clinical psychologists. 
PATIENTS’ CONCERNS AND ATTITUDES REGARDING 
THE RISK OF INFERTILITY
Fertility-related psychological distress persists from diagnosis 
through survivorship. Previous research suggested that female 
cancer survivors presented high rates of uncertainty, worry, 
stress, anger, anxiety, nervousness, and fear related to the un-
known fertility status [33, 34]. Moreover, some patients report 
constant and persistent reproductive concerns that disrupt their 
life purpose with the knowledge that cancer may affect their 
lives forever [35]. 
Several studies focused on exploring the sociodemographic and 
clinical characteristics related to the risk of infertility, revealing 
that younger patients, highly educated, unmarried, professionally 
active, childless, who wish to have children and who previously 
had trouble getting pregnant before cancer, are the most con-
cerned about the impact of anticancer treatments on fertility [36]. 
young and childless women revealed a higher desire to become 
pregnant after breast cancer compared to women who already 
had children and who seemed to be more concerned about the 
possibility of recurrence [37, 38]. Regarding clinical variables, 
studies were mainly focused on time since diagnosis, cancer 
stage, disease dissemination and the quality of the information 
received, as factors correlated with infertility concerns and will-
ingness to undergo fertility preservation procedures. Thus, when 
dealing with a cancer diagnosis and, especially in a situation of 
early-stage cancer, women revealed to be less concerned about 
fertility preservation, while being more focused on anticancer 
treatment and survival [37, 39]. considering the disease stage, 
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studies hypothesized that higher cancer stages (and, therefore, 
with a higher risk of recurrence) were associated with greater ac-
ceptance of cancer treatments and its side effects [37]. Even so, 
fertility is important regardless of cancer stage and, therefore, the 
opportunity for preservation should be openly discussed with 
these patients as well [11]. 
Regarding patients’ attitudes towards fertility preservation, the 
European organization for Research and Treatment of cancer 
developed a study aiming to evaluate the proportion of partici-
pants who would not agree to chemotherapy if it affected their 
fertility. The authors found that, although survival and cure were 
the priority for young women with cancer, fertility preservation 
emerged as a matter of great importance. Results revealed that 
59% of women wished to have children (or more children), com-
pared to 36% of women who do not want to have any more chil-
dren for fear of recurrence. Women who had an easier acceptance 
of the risk of infertility were women who already had children, did 
not intend to have more children, who were still waiting for the 
beginning of treatment (the initial stage of the disease), and living 
in Western Europe [37]. 
in general, female patients revealed more positive than nega-
tive attitudes towards fertility preservation, which leads to the 
hypothesis that they are receptive to decide in favor of fertility 
preservation procedures when correctly informed. 
PATIENT INFORMATION NEEDS REGARDING FERTILITY 
PRESERVATION
Research consistently reports that patients are generally unin-
formed about fertility preservation procedures, presenting low 
levels of literacy regarding this medical issue [27]. in a  recent 
study, 43% to 62% of female cancer survivors reported important 
unmet information needs, 26% felt that infertility risk was not well 
addressed by their doctors and revealed to be dissatisfied with 
the received information [32]. also, feeling overwhelmed with 
their cancer diagnosis, being unaware of the possible treatment 
impact on fertility, and the costs associated with these proce-
dures, were three important reasons for not undergoing fertility 
preservation [27]. Moreover, several female patients revealed nev-
er discussing this topic with their husband, family, friends, and/or 
health professionals because they felt that infertility risk was de-
valued and considered a minor issue when facing cancer [34, 38–
40]. additionally, patients older than 35 years and with children 
were less likely to be informed about preservation options, and 
several women did not recall having these conversations with 
their clinicians [27, 40]. 
There is a  consistent need to inform patients about the impact 
of the anticancer treatment on fertility and the existing preserva-
tion methods, regardless of their sociodemographic and clinical 
characteristics. Furthermore, some patients felt that there was 
a bias between the information that was delivered and the rele-
vance the clinicians gave to the subject. other patients revealed 
feeling pressured to start anticancer treatment and, therefore, 
not having enough time to make an informed decision [41]. This 
pressure could be the reflection of a judgment-bias regarding the 
clinicians’ perceptions when considering the importance patients 
gave to their fertility, after surviving cancer, which emphasizes the 
importance of how the information was delivered that could have 
impacted the patient’s decision-making processes. Moreover, the 
need for more information seems to be less prominent at diagno-
sis, but increases during and after systemic anticancer treatments 
[42]. after treatment, patients seem to recognize the importance 
of discussing fertility before the beginning of the treatment and 
revealed some disappointment regarding the quality and quanti-
ty of the information received [42]. although fertility was not the 
priority at diagnosis, some women revealed regret for not choos-
ing to consider preservation when it was possible. Research on 
decisional regret confirmed that women’s perspectives on fertility 
change over time, from the perception that procreation was not 
important to feeling regret over not having pursued conservation 
[42]. These studies also revealed that pre-treatment fertility satis-
factory counseling leads to lower levels of post-treatment regret 
and better quality of life [43]. 
lack of information regarding fertility risks can have important 
psychosocial consequences [42], and lead to patient’s uncertainty, 
depression, anxiety, distress, anger, and confusion [1, 12]. in this 
sense, fertility counseling has a fundamental role in assisting with 
fertility decision-making, but also in supporting patients with the 
psychological distress caused by the uncertainty of infertility [12]. 
More research is needed to understand what are the deci-
sion-making factors underlying fertility preservation. Research 
available is mostly cross-sectional and retrospective and there is 
a lack of longitudinal studies that may contribute to better knowl-
edge about patients’ concerns, needs, and attitudes regarding in-
fertility risks, as well as how it evolves. Research should also focus 
on exploring individual risk factors for decision-regret in women 
with cancer of childbearing age and what are their future expec-
tations regarding their reproductive capability and family plans. 
only then, clinicians will have clear guidelines on how to educate 
patients about fertility preservation alerting for the possibility 
of  mind-changing processes, while encouraging the discussion 
of situations that might not seem urgent at the moment of diag-
nosis but will affect the long-term quality of life.
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IMPACT OF THE RISK OF INFERTILITY ON THE 
PATIENT’S QUALITY OF LIFE
Recent studies indicated that the potential for fertility loss may be 
more stressful than a cancer diagnosis itself [1]. infertility seems to 
be associated with high levels of distress, anxiety, and depression 
[12], and lower quality of life [1]. it has also been identified as an 
experience marked by feelings of grief and loss, even in women 
who have fulfilled their family wishes before cancer [22]. Especial-
ly young and childless women, revealed higher levels of psycho-
logical distress, lower self-esteem, uncertainty, relationship prob-
lems, more intrusive thoughts, and more avoidance strategies 
[1, 12, 25, 42], regardless of the cancer site.
it is important to mention that some studies revealed that even 
women who already had children and who did not think about 
having more children after cancer, also face the risk of fertility loss 
as an emotionally draining experience [22, 25, 42]. Even though 
70% of patients revealed that the disease had no impact on their 
desire to have children, 13% to 15% stated that cancer diagnosis 
increased their desire to be mothers again and the value given to 
parenting [42]. 
in summary, few studies have evaluated the impact of fertility on 
female survivors’ quality of life, including childhood cancer survi-
vors. little is known about the psychological impact of infertility 
risk during and after cancer treatment, or which individual varia-
bles can potentially protect or impact the quality of life in these 
situations. infertility in young women with cancer is another set-
back to their personal and relational development considered 
another great loss caused by cancer. Therefore, it is important 
to better understand the impact of infertility in patients’ overall 
functioning, so that strategies can be developed to facilitate doc-
tor/patient’s communication processes and patients informed 
decision-making.
LIMITATIONS
a  comprehensive literature review has some limitations that 
need to be acknowledged. This type of study is not as exhaus-
tive as a systematic review. in this sense, a strict protocol was not 
followed and studies were selected based on their relevance re-
garding the theme of this review. no inclusion or exclusion criteria 
regarding population, design, or outcomes were explicitly con-
sidered for the selection of studies. instead, the authors adopted 
a broader perspective and analyzed the studies retrieved from the 
databases based on their pertinence and team consensus. This in-
creases the possibility of selection bias. in addition, only female 
fertility was considered. Future studies should focus on summa-
rizing recent data regarding male fertility issues, since an update 
on this matter is also needed. 
CONCLUSION 
Several studies confirmed the importance of biological parenting 
for female cancer patients of reproductive age. This comprehen-
sive review emphasized that the risk of infertility exceeds the di-
agnostic and clinical dimension of cancer, and is of great signif-
icance for female patients since it endangers a fundamental life 
goal for most women: the opportunity of biological motherhood 
which has several psychological, social, and spiritual implications 
for the couple and the family.
The risk of infertility seems to increase the psychological distress 
associated with a  cancer diagnosis, regardless of the patients’ 
parental status, since it interferes with women’s ability to decide 
about their life project regarding reproducibility and was im-
posed by the disease process, instead of decision-making. There-
fore, even patients who did not intend to have children before the 
diagnosis can feel the loss and the anger associated with infer-
tility risk as a result of cancer and its treatment. Since fertility is 
usually described as an important part of the definition of being 
a woman, all patients should be informed about infertility risk due 
to anticancer treatment, regardless of whether or not they have 
decided to have more children in the future.
Future studies should also identify an optimal approach to in-
clude fertility counseling and support resources into patients and 
survivor’s care programs. infertility risk should also be included 
in informed consent about anticancer treatment, especially be-
fore chemotherapy. Therefore, there is a  need to develop infor-
mational materials, clinical guidance, and multidisciplinary con-
sultations to facilitate communication between physicians and 
patients. More information is also needed on which individual 
and contextual factors might influence female cancer survivors’ 
decision-making to undergo or not fertility preservation. Studies 
are also needed to assess and characterize young cancer patients’ 
concerns about their infertility risk, their expectations of fertility, 
their informational needs, and attitudes towards childbearing 
during and after anticancer treatment.
IMPLICATIONS FOR PSYCHOSOCIAL ONCOLOGY
Health professionals should not make assumptions regarding fer-
tility, since studies consistently indicate that patients, regardless 
of their clinical and sociodemographic characteristics, assess pos-
itively the possibility of discussing this issue with their oncologist. 
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as a result, patients become more satisfied with the health care 
they received, regardless of choosing or not to preserve fertility. 
additionally, an oncologist should consider that discussing infer-
tility risk with patients does not decrease treatment adherence 
and, therefore, all the risks, options and benefits, should be clear-
ly and carefully addressed, ensuring that the patient makes an 
informed decision. although patients may be more focused on 
their diagnosis, oncologists should advise patients regarding po-
tential fertility threats, present them with different options, and 
prevent future regrets. 
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